Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 176.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,176 shares of the life sciences company’s stock after acquiring an additional 4,579 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Illumina were worth $749,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares during the last quarter. Baillie Gifford & Co. boosted its holdings in Illumina by 8.7% during the first quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock worth $787,725,000 after buying an additional 460,649 shares in the last quarter. Bank of New York Mellon Corp grew its position in Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after buying an additional 204,043 shares during the last quarter. Capital World Investors increased its holdings in shares of Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after buying an additional 801,814 shares in the last quarter. Finally, Primecap Management Co. CA lifted its position in shares of Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after acquiring an additional 1,997,010 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ILMN shares. Royal Bank of Canada restated an “outperform” rating and issued a $242.00 target price on shares of Illumina in a report on Wednesday, August 14th. Piper Sandler dropped their price target on Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Evercore ISI reduced their price objective on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $120.00 to $154.00 in a research report on Friday, August 16th. Finally, StockNews.com began coverage on shares of Illumina in a report on Thursday, August 29th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $152.05.

Illumina Price Performance

ILMN opened at $141.43 on Friday. The stock has a fifty day moving average price of $128.14 and a 200 day moving average price of $120.61. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $148.19. The stock has a market cap of $22.53 billion, a price-to-earnings ratio of -17.35 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the company earned $0.32 EPS. The firm’s revenue was down 5.4% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post 3.63 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.